2024

1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

   International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

2. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

   Experimental Dermatology, Vol. 33, Núm. 8